<!DOCTYPE html>
<html lang="en"><head>
<script src="6_Hepatitis_viruses_files/libs/clipboard/clipboard.min.js"></script>
<script src="6_Hepatitis_viruses_files/libs/quarto-html/tabby.min.js"></script>
<script src="6_Hepatitis_viruses_files/libs/quarto-html/popper.min.js"></script>
<script src="6_Hepatitis_viruses_files/libs/quarto-html/tippy.umd.min.js"></script>
<link href="6_Hepatitis_viruses_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="6_Hepatitis_viruses_files/libs/quarto-html/light-border.css" rel="stylesheet">
<link href="6_Hepatitis_viruses_files/libs/quarto-html/quarto-syntax-highlighting-065a5179aebd64318d7ea99d77b64a9e.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="6_Hepatitis_viruses_files/libs/quarto-contrib/roughnotation-0.5.1/rough-notation.iife.js"></script>
<script src="6_Hepatitis_viruses_files/libs/quarto-contrib/roughnotation-init-1.0.0/rough.js"></script><meta charset="utf-8">
  <meta name="generator" content="quarto-1.8.25">

  <meta name="dcterms.date" content="2025-10-30">
  <title>Hepatitis Viruses</title>
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
  <link rel="stylesheet" href="6_Hepatitis_viruses_files/libs/revealjs/dist/reset.css">
  <link rel="stylesheet" href="6_Hepatitis_viruses_files/libs/revealjs/dist/reveal.css">
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      width: 0.8em;
      margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
      vertical-align: middle;
    }
    /* CSS for citations */
    div.csl-bib-body { }
    div.csl-entry {
      clear: both;
    }
    .hanging-indent div.csl-entry {
      margin-left:2em;
      text-indent:-2em;
    }
    div.csl-left-margin {
      min-width:2em;
      float:left;
    }
    div.csl-right-inline {
      margin-left:2em;
      padding-left:1em;
    }
    div.csl-indent {
      margin-left: 2em;
    }  </style>
  <link rel="stylesheet" href="6_Hepatitis_viruses_files/libs/revealjs/dist/theme/quarto-0fde88a82f0356838740f155f1088782.css">
  <link rel="stylesheet" href="../styles.css">
  <link href="6_Hepatitis_viruses_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.css" rel="stylesheet">
  <link href="6_Hepatitis_viruses_files/libs/revealjs/plugin/reveal-menu/menu.css" rel="stylesheet">
  <link href="6_Hepatitis_viruses_files/libs/revealjs/plugin/reveal-menu/quarto-menu.css" rel="stylesheet">
  <link href="6_Hepatitis_viruses_files/libs/revealjs/plugin/reveal-quiz/quiz.css" rel="stylesheet">
  <link href="6_Hepatitis_viruses_files/libs/revealjs/plugin/appearance/appearance.css" rel="stylesheet">
  <link href="6_Hepatitis_viruses_files/libs/revealjs/plugin/verticator/verticator.css" rel="stylesheet">
  <link href="6_Hepatitis_viruses_files/libs/revealjs/plugin/reveal-pointer/pointer.css" rel="stylesheet">
  <link href="6_Hepatitis_viruses_files/libs/revealjs/plugin/quarto-support/footer.css" rel="stylesheet">
  <style type="text/css">
    .reveal div.sourceCode {
      margin: 0;
      overflow: auto;
    }
    .reveal div.hanging-indent {
      margin-left: 1em;
      text-indent: -1em;
    }
    .reveal .slide:not(.center) {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide.scrollable {
      overflow-y: auto;
    }
    .reveal .footnotes {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide .absolute {
      position: absolute;
      display: block;
    }
    .reveal .footnotes ol {
      counter-reset: ol;
      list-style-type: none; 
      margin-left: 0;
    }
    .reveal .footnotes ol li:before {
      counter-increment: ol;
      content: counter(ol) ". "; 
    }
    .reveal .footnotes ol li > p:first-child {
      display: inline-block;
    }
    .reveal .slide ul,
    .reveal .slide ol {
      margin-bottom: 0.5em;
    }
    .reveal .slide ul li,
    .reveal .slide ol li {
      margin-top: 0.4em;
      margin-bottom: 0.2em;
    }
    .reveal .slide ul[role="tablist"] li {
      margin-bottom: 0;
    }
    .reveal .slide ul li > *:first-child,
    .reveal .slide ol li > *:first-child {
      margin-block-start: 0;
    }
    .reveal .slide ul li > *:last-child,
    .reveal .slide ol li > *:last-child {
      margin-block-end: 0;
    }
    .reveal .slide .columns:nth-child(3) {
      margin-block-start: 0.8em;
    }
    .reveal blockquote {
      box-shadow: none;
    }
    .reveal .tippy-content>* {
      margin-top: 0.2em;
      margin-bottom: 0.7em;
    }
    .reveal .tippy-content>*:last-child {
      margin-bottom: 0.2em;
    }
    .reveal .slide > img.stretch.quarto-figure-center,
    .reveal .slide > img.r-stretch.quarto-figure-center {
      display: block;
      margin-left: auto;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-left,
    .reveal .slide > img.r-stretch.quarto-figure-left  {
      display: block;
      margin-left: 0;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-right,
    .reveal .slide > img.r-stretch.quarto-figure-right  {
      display: block;
      margin-left: auto;
      margin-right: 0; 
    }
  </style>
  <!-- Cursor tail extension: inline CSS + JS (red tail) -->
  <style>
  /* Cursor tail styles (red) */
  .ct-overlay{ position:absolute; inset:0; pointer-events:none; z-index:99999; }
  .ct-dot{ position: absolute; width:12px; height:12px; border-radius:50%; background: rgba(255,50,50,0.95); transform: translate(-50%, -50%); pointer-events:none; mix-blend-mode:normal; will-change:transform,opacity; opacity:0.95; transition: opacity 120ms linear, transform 120ms linear; }
  @media (hover: none){ .ct-dot{ display:none !important; } }
  @media (prefers-reduced-motion: reduce){ .ct-dot{ transition:none !important; } }
  </style>

  <script>
  // Cursor-tail extension script (red tail). Guarded to avoid duplicates.
  (function(){
    if (typeof window === 'undefined') return;
    if (window.__cursorTailExtensionIncluded) return; window.__cursorTailExtensionIncluded = true;
    try{
      if (window.matchMedia && window.matchMedia('(hover: none)').matches) return;
      if (window.matchMedia && window.matchMedia('(prefers-reduced-motion: reduce)').matches) return;

      function init(){
        try{
          var reveal = document.querySelector('.reveal');
          var container = document.body;
          var overlay = null;
          if (reveal){
            if (getComputedStyle(reveal).position === 'static') reveal.style.position = 'relative';
            overlay = document.createElement('div'); overlay.className = 'ct-overlay'; reveal.appendChild(overlay); container = overlay;
          }

          var NUM = 14, dots = [], mouseX=-1000, mouseY=-1000;
          for(var i=0;i<NUM;i++){
            var el = document.createElement('div'); el.className = 'ct-dot';
            var size = Math.max(6, 14 - i*0.6); el.style.width = el.style.height = size + 'px';
            el.style.opacity = String(1 - i/(NUM+2)); el.style.position = (container===document.body)?'fixed':'absolute';
            container.appendChild(el); dots.push({el:el,x:mouseX,y:mouseY});
          }

          window.addEventListener('mousemove', function(e){ mouseX = e.clientX; mouseY = e.clientY; }, {passive:true});

          function animate(){
            var x=mouseX,y=mouseY;
            for(var i=0;i<dots.length;i++){
              var d=dots[i]; var easing=0.18 + (i/(dots.length*6)); d.x += (x-d.x)*easing; d.y += (y-d.y)*easing;
              var localX = d.x - (container===document.body?0:container.getBoundingClientRect().left);
              var localY = d.y - (container===document.body?0:container.getBoundingClientRect().top);
              d.el.style.transform = 'translate3d('+localX+'px,'+localY+'px,0) translate(-50%, -50%)'; x=d.x;y=d.y;
            }
            requestAnimationFrame(animate);
          }
          requestAnimationFrame(animate);
        }catch(e){ console.error('cursor-tail extension init error', e); }
      }
      if (document.readyState === 'complete' || document.readyState === 'interactive') init(); else document.addEventListener('DOMContentLoaded', init);
    }catch(e){ console.error('cursor-tail extension error', e); }
  })();
  </script>
</head>
<body class="quarto-light">
  <div class="reveal">
    <div class="slides">

<section id="title-slide" data-background-color="#2c3e50" data-background-opacity="0.3" class="quarto-title-block center">
  <h1 class="title">Hepatitis Viruses</h1>

<div class="quarto-title-authors">
<div class="quarto-title-author">
<div class="quarto-title-author-name">
Sopheap Oeng 
</div>
<div class="quarto-title-author-email">
<a href="mailto:sopheap15@gmail.com">sopheap15@gmail.com</a>
</div>
</div>
</div>

  <p class="date">30 Oct 2025</p>
</section>
<section id="objectives" class="slide level2">
<h2>Objectives</h2>
<ul>
<li>Describe hepatitis virus morphology</li>
<li>Summarize key characteristics</li>
<li>Outline replication stages</li>
<li>Explain transmission routes</li>
<li>Identify infection risk factors</li>
<li>Describe pathogenesis and clinical course</li>
<li>List diagnostic methods</li>
<li>Summarize treatment options</li>
</ul>
</section>
<section id="introduction" class="slide level2">
<h2>Introduction</h2>
<ul>
<li>Hepatitis: viral liver inflammation (A-E and G)</li>
<li>Key signs: jaundice, fatigue, nausea, dark urine; ↑ liver enzymes</li>
<li>Transmission: fecal–oral (A, E); blood/sexual/perinatal (B, C, D, G)</li>
<li>Outcomes: A/E usually acute; B/C/D often chronic → cirrhosis and HCC risk</li>
<li>Diagnosis: liver tests, serology/PCR</li>
<li>Prevention: vaccines (A, B)</li>
<li>Treatment: antivirals (B, C), supportive care</li>
</ul>
</section>
<section id="introduction-cont." class="slide level2">
<h2>Introduction (cont.)</h2>
<iframe width="1200" height="650" src="https://www.youtube.com/embed/NvJk8KzI7eQ" title="https://www.youtube.com/embed/NvJk8KzI7eQ" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="">
</iframe>
</section>
<section id="comparative-features-of-hepatitis-viruses" class="slide level2">
<h2>Comparative features of hepatitis viruses</h2>

<img data-src="images/image3.png" style="display: block; margin-left: auto; margin-right: auto; border-radius: 8px;;width:100.0%" class="r-stretch"></section>
<section id="comparative-features-of-hepatitis-viruses-1" class="slide level2">
<h2>Comparative features of hepatitis viruses</h2>

<img data-src="images/image4.png" style="display: block; margin-left: auto; margin-right: auto; border-radius: 8px;;width:100.0%" class="r-stretch"></section>
<section>
<section id="hepatitis-a-virus" class="title-slide slide level1 center">
<h1>HEPATITIS A VIRUS</h1>

</section>
<section id="overview" class="slide level2">
<h2>Overview</h2>
<ul>
<li>Acute hepatitis by HAV (Picornaviridae, Hepatovirus)</li>
<li>Fecal–oral spread: contaminated food/water, shellfish, close contact</li>
<li>Incubation 15–50 days (≈25); children often asymptomatic</li>
<li>Dx: anti‑HAV IgM (acute); IgG = past infection/vaccine</li>
<li>99% of healthy adults self-limiting, develop lifelong immunity</li>
<li>Prevention: hygiene, immune globulin post‑exposure, inactivated vaccine</li>
</ul>
</section>
<section id="structure" class="slide level2">
<h2>Structure</h2>
<div class="columns">
<div class="column" style="width:60%;">
<ul>
<li>Virion: non-enveloped, icosahedral, ~27 nm</li>
<li>Genome: +ssRNA (~7.5 kb) with VPg at 5′ and poly(A) tail at 3′</li>
<li>Expression: single ORF → polyprotein, cleaved into structural (VP1–VP4) and nonstructural proteins</li>
<li>Environmental stability: acid- and solvent-resistant; persists in water/food; inactivated by chlorination, adequate heat (&gt;60 °C), formalin, or UV</li>
</ul>
</div><div class="column" style="width:40%;">
<p><img data-src="images/image5.png" style="width:100.0%"></p>
</div></div>
</section>
<section id="replication" class="slide level2">
<h2>Replication</h2>
<div class="columns">
<div class="column" style="width:60%;">
<ul>
<li>Receptor: TIM‑1 (HAVCR1) on hepatocytes</li>
<li>Entry: receptor‑mediated endocytosis → uncoating in endosome</li>
<li>Genome: +ssRNA (~7.5 kb, VPg‑linked) — serves as mRNA</li>
<li>Translation/replication: single ORF → polyprotein → proteolytic cleavage</li>
<li>Assembly/release: cytoplasmic capsid assembly; released non‑enveloped</li>
<li>Tropism: hepatocytes</li>
</ul>
</div><div class="column" style="width:40%;">
<p><img data-src="images/image6.gif" style="width:70.0%"></p>
</div></div>
</section>
<section id="pathogenesis" class="slide level2">
<h2>Pathogenesis</h2>

<img data-src="images/image7.png" style="width:70.0%" class="r-stretch"></section>
<section id="pathogenesis-and-immunity" class="slide level2">
<h2>Pathogenesis and immunity</h2>
<ul>
<li>Entry: ingestion → replicates in oropharyngeal/intestine → primary viremia → hepatocytes/Kupffer cells</li>
<li>Liver injury: immune‑mediated (T cells); minimal direct cytopathic effect</li>
<li>Shedding: high fecal viral load ~10–14 days before jaundice; peaks at symptom onset</li>
<li>Immunity: anti‑HAV IgM in acute, replaced by durable IgG → lifelong immunity</li>
<li>Outcome: usually self‑limited (incubation ~15–50 days); fulminant hepatitis rare (~0.1%)</li>
</ul>
</section>
<section id="epidemiology" class="slide level2">
<h2>Epidemiology</h2>
<ul>
<li>Reservoir: humans (chimpanzees experimentally susceptible)</li>
<li>Distribution: worldwide; highest where sanitation is poor</li>
<li>Risk factors: poor sanitation, contaminated food/water, crowded settings, travel</li>
<li>Outcomes/immunity: usually self‑limited; fulminant disease rare; anti‑HAV IgG = long‑lasting immunity</li>
</ul>
</section>
<section id="clinical-syndromes" class="slide level2">
<h2>Clinical syndromes</h2>
<ul>
<li>Most infections are asymptomatic, especially in children</li>
<li>Incubation/shedding: 15–50 days (mean ~25); fecal shedding peaks ~1–2 weeks before symptoms</li>
<li>Adults: abrupt onset of fever, fatigue, nausea, anorexia, and abdominal pain; jaundice in ~70–80%</li>
<li>Children (&lt;6 years): usually mild or asymptomatic; jaundice ≈10%</li>
<li>Course: symptoms intensify for several days before the icteric phase; ~99% recover, fulminant hepatitis is rare (~0.1%)</li>
</ul>
</section>
<section id="clinical-syndromes-1" class="slide level2">
<h2>Clinical syndromes</h2>

<img data-src="images/image8.png" style="display: block; margin-left: auto; margin-right: auto; border-radius: 8px;;width:100.0%" class="r-stretch"></section>
<section id="laboratory-diagnosis" class="slide level2">
<h2>Laboratory diagnosis</h2>
<ul>
<li>Anti‑HAV IgM (EIA/ELISA) — indicates acute/recent infection</li>
<li>Anti‑HAV IgG — past infection or vaccine‑induced immunity</li>
<li>HAV RNA (RT‑PCR, stool or serum) — early detection and outbreak/genotyping</li>
<li>Specimens: serum/plasma for serology; stool or serum for PCR</li>
</ul>
</section>
<section id="treatment-prevention-and-control" class="slide level2">
<h2>Treatment, prevention, and control</h2>
<ul>
<li>Treatment: supportive care — rest, fluids, nutrition</li>
<li>Prevent fecal–oral spread: safe water and food, hand hygiene, avoid raw shellfish</li>
<li>Water: boil or chlorinate to inactivate HAV</li>
<li>Post‑exposure: immune globulin within 2 weeks</li>
<li>Vaccination: inactivated vaccine, recommended for travelers and high‑risk groups</li>
</ul>
</section></section>
<section>
<section id="hepatitis-b-virus" class="title-slide slide level1 center">
<h1>HEPATITIS B VIRUS</h1>

</section>
<section id="overview-1" class="slide level2 font14">
<h2>Overview</h2>
<ul>
<li>Hepatitis B in family <em>Hepadnaviridae</em></li>
<li>Tropism: primarily hepatocytes</li>
<li>Transmission: blood, sexual contact, perinatal</li>
<li>Incubation: 6 weeks–6 months (average ~90 days)</li>
<li>Chronicity: ~5–10% in adults; up to 90% in perinatal infections</li>
<li>Complications: cirrhosis and hepatocellular carcinoma</li>
<li>Diagnosis: HBsAg, HBeAg, anti-HBc, HBV DNA testing</li>
</ul>
<div class="callout callout-note callout-titled callout-style-default">
<div class="callout-body">
<div class="callout-title">
<div class="callout-icon-container">
<i class="callout-icon"></i>
</div>
<p><strong>Note</strong></p>
</div>
<div class="callout-content">
<p>Global burden: &gt;250 million chronic infections and ~1 million deaths/year</p>
</div>
</div>
</div>
</section>
<section id="overview-start-3.30---10.37min-cont." class="slide level2">
<h2>Overview start 3.30 -&gt; 10.37min (cont.)</h2>
<iframe width="1200" height="650" src="https://www.youtube.com/embed/tuWWtTuc2cw" title="https://www.youtube.com/embed/tuWWtTuc2cw" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="">
</iframe>
</section>
<section id="structure-1" class="slide level2 smaller">
<h2>Structure</h2>
<div class="columns">
<div class="column" style="width:60%;">
<ul>
<li>Genome: dsDNA ≈3.2 kb; repairs to cccDNA in nucleus</li>
<li>Particles
<ul>
<li>Dane (envelop + core + DNA): infectious enveloped virion (~42 nm)</li>
<li>Subviral (envelop only): noninfectious HBsAg spheres/filaments (abundant)</li>
</ul></li>
<li>Proteins
<ul>
<li>HBsAg (S/M/L): envelope, attachment, vaccine target</li>
<li>HBcAg: capsid</li>
<li>HBeAg: secreted marker of active replication</li>
<li>Polymerase (P): primer + reverse transcriptase + RNase H</li>
<li>HBx: regulatory, linked to pathogenesis/oncogenesis</li>
</ul></li>
</ul>
</div><div class="column" style="width:40%;">
<p><img data-src="images/image_dane.png" style="width:80.0%"></p>
</div></div>
<!-- ## Structure

![](images/image9.png){ width=70% }

![](images/image10.png){ width=70% }

![](images/image11.png){ width=70% }

![](images/image12.png){ width=70% }

![](images/image13.png){ width=70% } -->
</section>
<section id="replication-1" class="slide level2">
<h2>Replication</h2>
<ul>
<li>Tropism: hepatocytes</li>
<li>Entry: endocytosis → nucleocapsid to nucleus</li>
<li>Genome: partial ds rcDNA → repaired to cccDNA</li>
<li>Transcription/replication: host Pol II → pgRNA; viral RT → rcDNA</li>
<li>Assembly/release: bud into ER/Golgi, acquire HBsAg; excess subviral HBsAg released</li>
<li>Integration: occasional host DNA integration → oncogenesis</li>
</ul>
</section>
<section id="replication-cont." class="slide level2">
<h2>Replication (cont.)</h2>
<p><img data-src="images/image14.png" class="absolute" style="left: 300px; width: 320px; "></p>
<p><img data-src="images/image15.png" class="absolute" style="right: 300px; width: 320px; "></p>
</section>
<section id="pathogenesis-and-immunity-1" class="slide level2">
<h2>Pathogenesis and immunity</h2>
<ul>
<li>Outcomes: asymptomatic, acute, or chronic disease</li>
<li>Transmission: blood, sexual, perinatal; virus present in various body fluids</li>
<li>Liver injury: immune‑mediated; HBV itself is minimally cytopathic</li>
<li>Incubation: weeks–months (≈90 days); cccDNA persistence enables latency</li>
<li>Clearance requires strong multispecific CD4+/CD8+ responses + anti‑HBs; weak/tolerant responses → chronicity</li>
<li>Chronic sequelae: fibrosis, cirrhosis, HCC; HBeAg/HBsAg indicate high replication</li>
</ul>
</section>
<section id="pathogenesis-and-immunity-2" class="slide level2">
<h2>Pathogenesis and immunity</h2>
<ul>
<li>Acute: hepatocellular swelling</li>
<li>Infiltrate: lymphocytes with Kupffer cell activation</li>
<li>Injury: immune‑mediated cytotoxic T cell killing, minimal direct viral cytopathy</li>
<li>Resolution: strong CD4+/CD8+ responses and anti‑HBs → viral clearance and regeneration</li>
<li>Chronicity: weak/tolerant immunity → persistent infection, fibrosis, cirrhosis, ↑ HCC risk</li>
<li>Markers: HBeAg and high HBV DNA = active replication; HBsAg loss and anti‑HBs = recovery</li>
</ul>
</section>
<section id="pathogenesis-1" class="slide level2">
<h2>Pathogenesis</h2>

<img data-src="images/image16.png" style="display: block; margin-left: auto; margin-right: auto; border-radius: 8px;;width:100.0%" class="r-stretch"></section>
<section id="epidemiology-1" class="slide level2 font14">
<h2>Epidemiology</h2>
<ul>
<li>Global burden: ~296 million chronically infected; ~820,000 deaths/year</li>
<li>Highest prevalence: sub‑Saharan Africa, East/Southeast Asia, Amazon, Pacific Islands</li>
<li>Main transmission routes: perinatal (mother→infant), early‑childhood, sexual contact, percutaneous exposures (blood, unsafe injections, IDU)</li>
<li>High‑risk groups: infants of HBsAg+ mothers, people from endemic regions, people who inject drugs, MSM, healthcare workers, hemodialysis/transfusion recipients</li>
<li>Key controls: timely birth‑dose and routine infant vaccination, maternal screening + antivirals in pregnancy, safe blood/injection practices, harm‑reduction services</li>
</ul>
</section>
<section id="clinical-syndromes-for-acute-infection" class="slide level2 font14">
<h2>Clinical syndromes for acute infection</h2>
<ul>
<li>Incubation: prolonged (weeks–months); often insidious onset</li>
<li>Prodrome: fever, malaise, anorexia → nausea, vomiting, abdominal discomfort, myalgias</li>
<li>Icteric phase: jaundice, dark urine, pale stools, pruritus</li>
<li>Course: severity variable; adults more often symptomatic than children</li>
<li>Fulminant hepatitis: rare (~1%) — acute liver failure with encephalopathy, coagulopathy, ascites, and bleeding</li>
<li>Immune‑complex–mediated extrahepatic manifestations: rash, arthralgia/polyarthritis, serum‑sickness–like illness, necrotizing vasculitis, and glomerulonephritis</li>
</ul>
</section>
<section id="clinical-syndrom-for-chronic-infection-cont." class="slide level2 font14">
<h2>Clinical syndrom for chronic infection (cont.)</h2>
<ul>
<li>Progression: ~5–10% of adult infections become chronic; much higher after perinatal exposure</li>
<li>Clinical states:
<ul>
<li>Inactive carrier: HBsAg positive with low/undetectable HBV DNA and normal ALT — minimal ongoing liver injury</li>
<li>Chronic active hepatitis: persistent inflammation → progressive fibrosis, cirrhosis, liver failure</li>
</ul></li>
<li>Complications: cirrhosis and HCC. Mechanisms include chronic inflammation and occasional viral DNA integration into the host genom</li>
<li>Latency to HCC: highly variable (reported ≈9–35 years or longer)</li>
</ul>
</section>
<section id="clinical-syndromes-for-chronic-infection-cont." class="slide level2">
<h2>Clinical syndromes for chronic infection (cont.)</h2>

<!-- ![](images/image18.png){ width=70% }

![](images/image19.png){ width=70% }

![](images/image20.png){ width=70% }

![](images/image21.png){ width=70% } -->
<img data-src="images/image_a_and_c.png" style="display: block; margin-left: auto; margin-right: auto; border-radius: 8px;;width:100.0%" class="r-stretch"></section>
<section id="laboratory-diagnosis-1" class="slide level2">
<h2>Laboratory diagnosis</h2>
<ul>
<li>Initial evaluation
<ul>
<li>Clinical assessment + LFTs ALT AST ALP total bilirubin</li>
<li>CBC and coagulation INR if severe</li>
</ul></li>
<li>Staging and specimens
<ul>
<li>FibroScan or liver biopsy for fibrosis</li>
<li>Serum or plasma for testing</li>
</ul></li>
<li>Molecular testing
<ul>
<li>HBV DNA quantitative PCR — viral load and treatment guide</li>
<li>Genotype testing when indicated</li>
</ul></li>
</ul>
</section>
<section id="laboratory-diagnosis-cont." class="slide level2">
<h2>Laboratory diagnosis (cont.)</h2>
<ul>
<li>Serology
<ul>
<li>HBsAg — current infection</li>
<li>HBeAg — high replication and infectivity</li>
<li>Anti-HBs — immunity from recovery or vaccine</li>
<li>Anti-HBc IgM — recent infection</li>
<li>Anti-HBc total — prior or current infection not from vaccine</li>
</ul></li>
</ul>

<img data-src="images/image22.png" style="display: block; margin-left: auto; margin-right: auto; border-radius: 8px;;width:100.0%" class="r-stretch"><aside class="notes">
<ul>
<li>HBeAg: secreted during active replication; indicates high infectivity</li>
<li>Anti-HBc IgM: marker of recent infection; persists ~6 months</li>
</ul>
<style type="text/css">
        span.MJX_Assistive_MathML {
          position:absolute!important;
          clip: rect(1px, 1px, 1px, 1px);
          padding: 1px 0 0 0!important;
          border: 0!important;
          height: 1px!important;
          width: 1px!important;
          overflow: hidden!important;
          display:block!important;
      }</style></aside>
</section>
<section id="treatment-prevention-and-control-1" class="slide level2 font14">
<h2>Treatment prevention and control</h2>
<ul>
<li>Acute HBV
<ul>
<li>Supportive care and monitoring</li>
<li>Antivirals for fulminant or severe disease per specialist</li>
</ul></li>
<li>Chronic HBV
<ul>
<li>Goals suppress viral replication prevent progression to cirrhosis and HCC</li>
<li>First-line antivirals tenofovir disoproxil fumarate TDF tenofovir alafenamide TAF entecavir</li>
<li>Pegylated interferon for selected patients</li>
<li>Avoid agents with high resistance when possible</li>
</ul></li>
</ul>
</section>
<section id="treatment-prevention-and-control-cont." class="slide level2 font14">
<h2>Treatment prevention and control (cont.)</h2>
<ul>
<li>Prevention and public health
<ul>
<li>Universal infant vaccination with timely birth dose within 24 hours</li>
<li>HBIG plus vaccine for infants of HBsAg positive mothers</li>
<li>Screening of blood organ donors and pregnant women</li>
<li>Safe injection practices needle exchange harm reduction and safe sex counseling</li>
</ul></li>
<li>Patient counselling
<ul>
<li>Explain transmission routes alcohol avoidance and adherence to monitoring and therapy</li>
<li>Refer to hepatology or infectious diseases for treatment and long term follow up</li>
</ul></li>
</ul>
</section></section>
<section>
<section id="hepatitis-c-viruses" class="title-slide slide level1 center">
<h1>HEPATITIS C VIRUSES</h1>

</section>
<section id="overview-2" class="slide level2">
<h2>Overview</h2>
<ul>
<li>Major cause of non‑A/non‑B hepatitis, formerly common post‑transfusion</li>
<li>~170 million global carriers, ~4 million in US</li>
<li>Bloodborne transmission with high chronicity</li>
<li>Chronic infection → cirrhosis and hepatocellular carcinoma</li>
<li>Incubation 6–12 weeks</li>
</ul>
</section>
<section id="structure-2" class="slide level2">
<h2>Structure</h2>
<div class="columns">
<div class="column" style="width:60%;">
<ul>
<li>Genus Hepacivirus</li>
<li>Family Flaviviridae</li>
<li>Size 30–60 nm</li>
<li>Envelope, icosahedral</li>
<li>Genome +ssRNA ~9.1 kb single ORF</li>
<li>Encodes ~10 proteins</li>
<li>Envelope glycoproteins E1 E2</li>
</ul>
</div><div class="column" style="width:40%;">
<p><img data-src="images/image24.png" style="width:70.0%"></p>
</div></div>
</section>
<section id="replication-2" class="slide level2 font14">
<h2>Replication</h2>
<div class="columns">
<div class="column" style="width:65%;">
<ul>
<li>Host: humans and chimpanzees; tropism: hepatocytes</li>
<li>Entry: receptor-mediated endocytosis and endosomal fusion</li>
<li>Genome: +ssRNA functions as mRNA → translated → polyprotein</li>
<li>Replication: (+)RNA → dsRNA replicative intermediate → new (+) genomes</li>
<li>Assembly/release: buds into ER as lipoviroparticles, secreted via VLDL pathway</li>
<li>Immune evasion: inhibits IFN signaling and apoptosis (PKR, TNF pathways)</li>
</ul>
</div><div class="column" style="width:35%;">
<p><img data-src="images/image27.jpg" style="width:100.0%"></p>
</div></div>
<!-- ![](images/image25.jpeg){ width=70% }
![](images/image26.png){ width=70% } -->
</section>
<section id="pathogenesis-and-immunity-3" class="slide level2 font14">
<h2>Pathogenesis and immunity</h2>
<ul>
<li>Invades B and T lymphocytes and monocytes then infects hepatocytes</li>
<li>Promotes cell survival leading to persistent infection</li>
<li>Cell-mediated immunity mediates viral clearance and liver injury</li>
<li>Chronic infection exhausts CD8 T cells and impairs viral elimination</li>
<li>Histology shows inflammation, portal and periportal fibrosis, and lobular necrosis</li>
<li>Chronic inflammation and regeneration increase hepatocellular carcinoma risk</li>
<li>Anti-HCV antibodies are not protective</li>
</ul>
</section>
<section id="epidemiology-2" class="slide level2">
<h2>Epidemiology</h2>
<ul>
<li>Transmission: bloodborne, sexual</li>
<li>High risk: people who inject drugs, transfusion/organ recipients, tattoo recipients, hemophiliacs</li>
<li>Global burden: ~58 million chronically infected, ~350k deaths/year</li>
</ul>
</section>
<section id="clinical-syndromes-2" class="slide level2">
<h2>Clinical syndromes</h2>
<ul>
<li>Acute: often asymptomatic; ~15% clear infection</li>
<li>Chronic: ~70–80% progress to chronic infection with risk of cirrhosis and HCC</li>
<li>Common symptom: persistent fatigue</li>
</ul>
</section>
<section id="diagnosis" class="slide level2">
<h2>Diagnosis</h2>
<ul>
<li>Anti‑HCV antibody screening, confirm with HCV RNA by RT-PCR</li>
<li>Use viral load for treatment monitoring</li>
</ul>
</section>
<section id="treatment-and-prevention" class="slide level2">
<h2>Treatment and prevention</h2>
<ul>
<li>Direct‑acting antivirals (E.g Glecaprevir) achieve cure in &gt;90% of cases</li>
<li>Prevent: blood screening, harm reduction (needle programs), safe tattooing, avoid alcohol</li>
</ul>
</section></section>
<section>
<section id="hepatitis-g-virus" class="title-slide slide level1 center">
<h1>HEPATITIS G VIRUS</h1>

</section>
<section id="overview-transmission" class="slide level2">
<h2>Overview &amp; transmission</h2>
<ul>
<li>GBV‑C (human pegivirus, HPgV) — enveloped, +ssRNA, ≈9.3 kb</li>
<li>Bloodborne, sexual, and perinatal spread</li>
<li>Often chronic and asymptomatic</li>
</ul>
</section>
<section id="clinical-significance" class="slide level2">
<h2>Clinical significance</h2>
<ul>
<li>No consistent link to clinical hepatitis</li>
<li>Clearance associated with anti‑E2 antibodies</li>
</ul>
</section>
<section id="diagnosis-1" class="slide level2">
<h2>Diagnosis</h2>
<ul>
<li>GBV‑C RNA by RT‑PCR for active infection</li>
<li>Anti‑E2 indicates prior cleared infection</li>
</ul>
</section>
<section id="treatment-prevention" class="slide level2">
<h2>Treatment &amp; prevention</h2>
<ul>
<li>No specific therapy or vaccine</li>
<li>Prevent via blood safety and infection control</li>
</ul>
<aside class="notes">
<p>This virus first discovered in patients with unexplained hepatitis in the 1990s. It is not linked to hepatitis. Name GBV-C: George Bush Hospital</p>
<style type="text/css">
        span.MJX_Assistive_MathML {
          position:absolute!important;
          clip: rect(1px, 1px, 1px, 1px);
          padding: 1px 0 0 0!important;
          border: 0!important;
          height: 1px!important;
          width: 1px!important;
          overflow: hidden!important;
          display:block!important;
      }</style></aside>
</section></section>
<section>
<section id="hepatitis-d-virus" class="title-slide slide level1 center">
<h1>HEPATITIS D VIRUS</h1>

</section>
<section id="overview-3" class="slide level2">
<h2>Overview</h2>
<ul>
<li>HDV infects ~15 million people worldwide and increases fulminant hepatitis risk</li>
<li>Defective satellite virus requiring HBsAg for assembly and spread</li>
<li>Relies on HBV for envelope and hepatocyte entry</li>
<li>Encodes one protein and depends on host enzymes for replication</li>
</ul>
</section>
<section id="structure-and-replication" class="slide level2 font14">
<h2>Structure and replication</h2>
<div class="columns">
<div class="column" style="width:65%;">
<ul>
<li>Genome: circular negative ssRNA ~1700 nt forming rodlike structure by base pairing</li>
<li>Virion: ~35–37 nm, delta Ag core wrapped by HBsAg envelope</li>
<li>Delta antigen: small 24 kDa and large 27 kDa forms with distinct roles</li>
<li>Replication: host RNA polymerase II transcribes genome, ribozyme cleavage, RNA editing generates large delta Ag for packaging</li>
</ul>
</div><div class="column" style="width:35%;">
<p><img data-src="images/image29.png" style="display: block; margin-left: auto; margin-right: auto; border-radius: 8px;;width:100.0%"></p>
</div></div>
</section>
<section id="pathogenesis-2" class="slide level2">
<h2>Pathogenesis</h2>
<ul>
<li>Occurs only with HBV coinfection or superinfection</li>
<li>Superinfection of chronic HBV often causes more severe and rapidly progressive liver disease</li>
<li>Liver injury from direct cytopathic effects of HDV plus immune mediated damage</li>
</ul>

<img data-src="images/image30.png" style="display: block; margin-left: auto; margin-right: auto; border-radius: 8px;;width:70.0%" class="r-stretch"></section>
<section id="diagnosis-2" class="slide level2">
<h2>Diagnosis</h2>
<ul>
<li>HDV RNA by RT‑PCR or anti‑HDV antibodies by ELISA</li>
<li>Test patients with acute or severe HBV disease and chronic HBV carriers with worsening liver injury</li>
</ul>
</section>
<section id="treatment-and-prevention-1" class="slide level2">
<h2>Treatment and prevention</h2>
<ul>
<li>No widely approved specific antiviral for HDV in many regions</li>
<li>Manage underlying HBV and refer to hepatology for emerging therapies and trials</li>
<li>Prevent HDV by HBV vaccination and blood safety measures</li>
</ul>
</section></section>
<section>
<section id="hepatitis-e-virus" class="title-slide slide level1 center">
<h1>HEPATITIS E VIRUS</h1>

</section>
<section id="hepatitis-e-virus-1" class="slide level2">
<h2>Hepatitis E virus</h2>
<ul>
<li>HEV: fecal–oral, waterborne outbreaks from contaminated water</li>
<li>Taxonomy: Hepeviridae, genus Hepevirus</li>
<li>Structure: nonenveloped icosahedral +ssRNA, ~27–34 nm</li>
<li>Epidemiology: outbreaks in low‑resource regions; sporadic zoonotic cases elsewhere</li>
<li>Genotypes: 1–2 mainly human (waterborne); 3–4 zoonotic (pigs)</li>
</ul>
</section>
<section id="hepatitis-e-virus-cont." class="slide level2">
<h2>Hepatitis E virus (cont.)</h2>
<ul>
<li>Clinical: acute, HAV‑like illness; usually not chronic in immunocompetent hosts</li>
<li>Severity: mortality ~1–2%; markedly higher (~20%) in third‑trimester pregnancy</li>
<li>Prevention: safe water, sanitation, hygiene; vaccine licensed in some countries</li>
<li>Diagnosis: anti‑HEV IgM and HEV RNA by RT-PCR for acute infection</li>
</ul>
</section></section>
<section>
<section id="quiz" class="title-slide slide level1 center">
<h1>Quiz</h1>

</section>
<section id="which-of-the-following-hepatitis-viruses-is-typically-transmitted-through-the-fecal-oral-route" class="slide level2 quiz-question">
<h2>Which of the following Hepatitis viruses is typically transmitted through the fecal-oral route?</h2>
<ul>
<li>Hepatitis B<br>
</li>
<li>Hepatitis C<br>
</li>
<li><span class="correct">Hepatitis A</span><br>
</li>
<li>Hepatitis D</li>
</ul>
</section>
<section id="which-hepatitis-virus-is-most-likely-to-cause-chronic-infection-in-adults" class="slide level2 quiz-question">
<h2>Which Hepatitis virus is most likely to cause chronic infection in adults?</h2>
<ul>
<li>Hepatitis A<br>
</li>
<li><span class="correct">Hepatitis B</span><br>
</li>
<li>Hepatitis E<br>
</li>
<li>Hepatitis G</li>
</ul>
</section>
<section id="what-is-the-primary-mode-of-transmission-for-hepatitis-c-virus" class="slide level2 quiz-question">
<h2>What is the primary mode of transmission for Hepatitis C virus?</h2>
<ul>
<li>Fecal-oral<br>
</li>
<li><span class="correct">Bloodborne</span><br>
</li>
<li>Sexual contact only<br>
</li>
<li>Airborne</li>
</ul>
</section>
<section id="which-hepatitis-virus-requires-coinfection-with-hepatitis-b-virus-to-replicate" class="slide level2 quiz-question">
<h2>Which Hepatitis virus requires coinfection with Hepatitis B virus to replicate?</h2>
<ul>
<li>Hepatitis A<br>
</li>
<li>Hepatitis C<br>
</li>
<li><span class="correct">Hepatitis D</span><br>
</li>
<li>Hepatitis E</li>
</ul>
</section>
<section id="what-is-the-most-effective-prevention-method-for-hepatitis-b-virus-infection" class="slide level2 quiz-question">
<h2>What is the most effective prevention method for Hepatitis B virus infection?</h2>
<ul>
<li>Hand washing<br>
</li>
<li><span class="correct">Vaccination</span><br>
</li>
<li>Safe water<br>
</li>
<li>Condom use</li>
</ul>
</section>
<section id="which-hepatitis-virus-has-the-highest-mortality-rate-during-pregnancy" class="slide level2 quiz-question">
<h2>Which Hepatitis virus has the highest mortality rate during pregnancy?</h2>
<ul>
<li>Hepatitis A<br>
</li>
<li>Hepatitis B<br>
</li>
<li>Hepatitis C<br>
</li>
<li><span class="correct">Hepatitis E</span></li>
</ul>
</section>
<section id="what-type-of-genome-does-hepatitis-b-virus-have" class="slide level2 quiz-question">
<h2>What type of genome does Hepatitis B virus have?</h2>
<ul>
<li>Single-stranded RNA<br>
</li>
<li>Double-stranded RNA<br>
</li>
<li>Single-stranded DNA<br>
</li>
<li><span class="correct">Double-stranded DNA</span></li>
</ul>
</section>
<section id="which-hepatitis-virus-is-classified-in-the-flaviviridae-family" class="slide level2 quiz-question">
<h2>Which Hepatitis virus is classified in the Flaviviridae family?</h2>
<ul>
<li>Hepatitis A<br>
</li>
<li>Hepatitis B<br>
</li>
<li><span class="correct">Hepatitis C</span><br>
</li>
<li>Hepatitis D</li>
</ul>
</section>
<section id="references" class="slide level2 smaller scrollable">
<h2>References</h2>
<ul>
<li>Adapted from training material: Chhay Sokdalis (PharmD).</li>
<li>Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. 7th ed.&nbsp;Elsevier; 2013.</li>
<li>Ryan KJ, Ray CG, editors. Sherris Medical Microbiology. 6th ed.&nbsp;McGraw-Hill; 2014.</li>
<li>Riedel S, Morse S, Mietzner T, Miller S, editors. Jawetz, Melnick &amp; Adelberg’s Medical Microbiology. McGraw-Hill; 2019.</li>
<li>Mishra B. Textbook of Medical Virology. 2nd ed.&nbsp;CBS Publishers &amp; Distributors; 2022.</li>
</ul>

<script> window._input_file = "---\n" + "title: \"Hepatitis Viruses\"\n" + "format:\n" + "  revealjs\n" + "---\n" + "\n" + "## Objectives\n" + "\n" + "- Describe hepatitis virus morphology\n" + "- Summarize key characteristics\n" + "- Outline replication stages\n" + "- Explain transmission routes\n" + "- Identify infection risk factors\n" + "- Describe pathogenesis and clinical course\n" + "- List diagnostic methods\n" + "- Summarize treatment options\n" + "\n" + "## Introduction\n" + "\n" + "- Hepatitis: viral liver inflammation (A-E and G)\n" + "- Key signs: jaundice, fatigue, nausea, dark urine; ↑ liver enzymes\n" + "- Transmission: fecal–oral (A, E); blood/sexual/perinatal (B, C, D, G)\n" + "- Outcomes: A/E usually acute; B/C/D often chronic → cirrhosis and HCC risk\n" + "- Diagnosis: liver tests, serology/PCR\n" + "- Prevention: vaccines (A, B)\n" + "- Treatment: antivirals (B, C), supportive care\n" + "\n" + "## Introduction (cont.)\n" + "<iframe width=\"1200\" height=\"650\" src=\"https://www.youtube.com/embed/NvJk8KzI7eQ\" title=\"https://www.youtube.com/embed/NvJk8KzI7eQ\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen></iframe>\n" + "\n" + "## Comparative features of hepatitis viruses\n" + "\n" + "![](images/image3.png){ width=100% style=\"display: block; margin-left: auto; margin-right: auto; border-radius: 8px;\" }\n" + "\n" + "## Comparative features of hepatitis viruses\n" + "\n" + "![](images/image4.png){ width=100% style=\"display: block; margin-left: auto; margin-right: auto; border-radius: 8px;\" }\n" + "\n" + "# HEPATITIS A VIRUS\n" + "\n" + "## Overview\n" + "\n" + "- Acute hepatitis by HAV (Picornaviridae, Hepatovirus)\n" + "- Fecal–oral spread: contaminated food/water, shellfish, close contact\n" + "- Incubation 15–50 days (≈25); children often asymptomatic\n" + "- Dx: anti‑HAV IgM (acute); IgG = past infection/vaccine\n" + "- 99% of healthy adults self-limiting, develop lifelong immunity\n" + "- Prevention: hygiene, immune globulin post‑exposure, inactivated vaccine\n" + "\n" + "## Structure\n" + ":::{.columns}\n" + ":::{.column width=\"60%\"}\n" + "- Virion: non-enveloped, icosahedral, ~27 nm\n" + "- Genome: +ssRNA (~7.5 kb) with VPg at 5′ and poly(A) tail at 3′\n" + "- Expression: single ORF → polyprotein, cleaved into structural (VP1–VP4) and nonstructural proteins\n" + "- Environmental stability: acid- and solvent-resistant; persists in water/food; inactivated by chlorination, adequate heat (>60 °C), formalin, or UV\n" + ":::\n" + ":::{.column width=\"40%\"}\n" + "![](images/image5.png){ width=100% }\n" + ":::\n" + ":::\n" + "\n" + "## Replication\n" + "\n" + ":::{.columns}\n" + ":::{.column width=\"60%\"}\n" + "- Receptor: TIM‑1 (HAVCR1) on hepatocytes\n" + "- Entry: receptor‑mediated endocytosis → uncoating in endosome\n" + "- Genome: +ssRNA (~7.5 kb, VPg‑linked) — serves as mRNA\n" + "- Translation/replication: single ORF → polyprotein → proteolytic cleavage\n" + "- Assembly/release: cytoplasmic capsid assembly; released non‑enveloped\n" + "- Tropism: hepatocytes\n" + ":::\n" + ":::{.column width=\"40%\"}\n" + "![](images/image6.gif){ width=70% }\n" + ":::\n" + ":::\n" + "\n" + "## Pathogenesis\n" + "\n" + "![](images/image7.png){ width=70% }\n" + "\n" + "## Pathogenesis and immunity\n" + "- Entry: ingestion → replicates in oropharyngeal/intestine → primary viremia → hepatocytes/Kupffer cells\n" + "- Liver injury: immune‑mediated (T cells); minimal direct cytopathic effect\n" + "- Shedding: high fecal viral load ~10–14 days before jaundice; peaks at symptom onset\n" + "- Immunity: anti‑HAV IgM in acute, replaced by durable IgG → lifelong immunity\n" + "- Outcome: usually self‑limited (incubation ~15–50 days); fulminant hepatitis rare (~0.1%)\n" + "\n" + "## Epidemiology\n" + "\n" + "- Reservoir: humans (chimpanzees experimentally susceptible)\n" + "- Distribution: worldwide; highest where sanitation is poor\n" + "- Risk factors: poor sanitation, contaminated food/water, crowded settings, travel\n" + "- Outcomes/immunity: usually self‑limited; fulminant disease rare; anti‑HAV IgG = long‑lasting immunity\n" + "\n" + "## Clinical syndromes \n" + "\n" + "- Most infections are asymptomatic, especially in children\n" + "- Incubation/shedding: 15–50 days (mean ~25); fecal shedding peaks ~1–2 weeks before symptoms\n" + "- Adults: abrupt onset of fever, fatigue, nausea, anorexia, and abdominal pain; jaundice in ~70–80%\n" + "- Children (<6 years): usually mild or asymptomatic; jaundice ≈10%\n" + "- Course: symptoms intensify for several days before the icteric phase; ~99% recover, fulminant hepatitis is rare (~0.1%)\n" + "\n" + "## Clinical syndromes\n" + "\n" + "![](images/image8.png){ width=100% style=\"display: block; margin-left: auto; margin-right: auto; border-radius: 8px;\" }\n" + "\n" + "## Laboratory diagnosis\n" + "\n" + "- Anti‑HAV IgM (EIA/ELISA) — indicates acute/recent infection\n" + "- Anti‑HAV IgG — past infection or vaccine‑induced immunity\n" + "- HAV RNA (RT‑PCR, stool or serum) — early detection and outbreak/genotyping\n" + "- Specimens: serum/plasma for serology; stool or serum for PCR\n" + "\n" + "## Treatment, prevention, and control\n" + "\n" + "- Treatment: supportive care — rest, fluids, nutrition\n" + "- Prevent fecal–oral spread: safe water and food, hand hygiene, avoid raw shellfish\n" + "- Water: boil or chlorinate to inactivate HAV\n" + "- Post‑exposure: immune globulin within 2 weeks\n" + "- Vaccination: inactivated vaccine, recommended for travelers and high‑risk groups\n" + "\n" + "\n" + "# HEPATITIS B VIRUS\n" + "\n" + "## Overview {.font14}\n" + "\n" + "- Hepatitis B in family _Hepadnaviridae_\n" + "- Tropism: primarily hepatocytes\n" + "- Transmission: blood, sexual contact, perinatal\n" + "- Incubation: 6 weeks–6 months (average ~90 days)\n" + "- Chronicity: ~5–10% in adults; up to 90% in perinatal infections\n" + "- Complications: cirrhosis and hepatocellular carcinoma\n" + "- Diagnosis: HBsAg, HBeAg, anti-HBc, HBV DNA testing\n" + "\n" + "::: {.callout-note}\n" + "Global burden: >250 million chronic infections and ~1 million deaths/year\n" + ":::\n" + "\n" + "## Overview start 3.30 -> 10.37min (cont.)\n" + "<iframe width=\"1200\" height=\"650\" src=\"https://www.youtube.com/embed/tuWWtTuc2cw\" title=\"https://www.youtube.com/embed/tuWWtTuc2cw\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen></iframe>\n" + "\n" + "## Structure {.smaller}\n" + "\n" + ":::{.columns}\n" + ":::{.column width=\"60%\"}\n" + "- Genome: dsDNA ≈3.2 kb; repairs to cccDNA in nucleus \n" + "- Particles\n" + "  - Dane (envelop + core + DNA): infectious enveloped virion (~42 nm)\n" + "  - Subviral (envelop only): noninfectious HBsAg spheres/filaments (abundant)\n" + "\n" + "- Proteins\n" + "  - HBsAg (S/M/L): envelope, attachment, vaccine target\n" + "  - HBcAg: capsid\n" + "  - HBeAg: secreted marker of active replication\n" + "  - Polymerase (P): primer + reverse transcriptase + RNase H\n" + "  - HBx: regulatory, linked to pathogenesis/oncogenesis\n" + ":::\n" + ":::{.column width=\"40%\"}\n" + "![](images/image_dane.png){ width=80% }\n" + ":::\n" + ":::\n" + "\n" + "\n" + "\n" + "\n" + "<!-- ## Structure\n" + "\n" + "![](images/image9.png){ width=70% }\n" + "\n" + "![](images/image10.png){ width=70% }\n" + "\n" + "![](images/image11.png){ width=70% }\n" + "\n" + "![](images/image12.png){ width=70% }\n" + "\n" + "![](images/image13.png){ width=70% } -->\n" + "\n" + "## Replication\n" + "\n" + "- Tropism: hepatocytes\n" + "- Entry: endocytosis → nucleocapsid to nucleus\n" + "- Genome: partial ds rcDNA → repaired to cccDNA\n" + "- Transcription/replication: host Pol II → pgRNA; viral RT → rcDNA\n" + "- Assembly/release: bud into ER/Golgi, acquire HBsAg; excess subviral HBsAg released\n" + "- Integration: occasional host DNA integration → oncogenesis\n" + "\n" + "## Replication (cont.)\n" + "\n" + "![](images/image14.png){ width=320px .absolute left=300px}\n" + "\n" + "![](images/image15.png){ width=320px .absolute right=300px}\n" + "\n" + "\n" + "## Pathogenesis and immunity\n" + "\n" + "- Outcomes: asymptomatic, acute, or chronic disease\n" + "- Transmission: blood, sexual, perinatal; virus present in various body fluids\n" + "- Liver injury: immune‑mediated; HBV itself is minimally cytopathic\n" + "- Incubation: weeks–months (≈90 days); cccDNA persistence enables latency\n" + "- Clearance requires strong multispecific CD4+/CD8+ responses + anti‑HBs; weak/tolerant responses → chronicity\n" + "- Chronic sequelae: fibrosis, cirrhosis, HCC; HBeAg/HBsAg indicate high replication\n" + "\n" + "## Pathogenesis and immunity\n" + "\n" + "- Acute: hepatocellular swelling\n" + "- Infiltrate: lymphocytes with Kupffer cell activation\n" + "- Injury: immune‑mediated cytotoxic T cell killing, minimal direct viral cytopathy\n" + "- Resolution: strong CD4+/CD8+ responses and anti‑HBs → viral clearance and regeneration\n" + "- Chronicity: weak/tolerant immunity → persistent infection, fibrosis, cirrhosis, ↑ HCC risk\n" + "- Markers: HBeAg and high HBV DNA = active replication; HBsAg loss and anti‑HBs = recovery\n" + "\n" + "## Pathogenesis\n" + "\n" + "![](images/image16.png){ width=100% style=\"display: block; margin-left: auto; margin-right: auto; border-radius: 8px;\" }\n" + "\n" + "## Epidemiology{.font14}\n" + "\n" + "- Global burden: ~296 million chronically infected; ~820,000 deaths/year\n" + "- Highest prevalence: sub‑Saharan Africa, East/Southeast Asia, Amazon, Pacific Islands\n" + "- Main transmission routes: perinatal (mother→infant), early‑childhood, sexual contact, percutaneous exposures (blood, unsafe injections, IDU)\n" + "- High‑risk groups: infants of HBsAg+ mothers, people from endemic regions, people who inject drugs, MSM, healthcare workers, hemodialysis/transfusion recipients\n" + "- Key controls: timely birth‑dose and routine infant vaccination, maternal screening + antivirals in pregnancy, safe blood/injection practices, harm‑reduction services\n" + "\n" + "\n" + "## Clinical syndromes for acute infection {.font14}\n" + "- Incubation: prolonged (weeks–months); often insidious onset\n" + "- Prodrome: fever, malaise, anorexia → nausea, vomiting, abdominal discomfort, myalgias\n" + "- Icteric phase: jaundice, dark urine, pale stools, pruritus\n" + "- Course: severity variable; adults more often symptomatic than children\n" + "- Fulminant hepatitis: rare (~1%) — acute liver failure with encephalopathy, coagulopathy, ascites, and bleeding\n" + "- Immune‑complex–mediated extrahepatic manifestations: rash, arthralgia/polyarthritis, serum‑sickness–like illness, necrotizing vasculitis, and glomerulonephritis\n" + "\n" + "## Clinical syndrom for chronic infection (cont.) {.font14}\n" + "- Progression: ~5–10% of adult infections become chronic; much higher after perinatal exposure\n" + "- Clinical states:\n" + "  - Inactive carrier: HBsAg positive with low/undetectable HBV DNA and normal ALT — minimal ongoing liver injury\n" + "  - Chronic active hepatitis: persistent inflammation → progressive fibrosis, cirrhosis, liver failure\n" + "- Complications: cirrhosis and HCC. Mechanisms include chronic inflammation and occasional viral DNA integration into the host genom\n" + "- Latency to HCC: highly variable (reported ≈9–35 years or longer)\n" + "\n" + "## Clinical syndromes for chronic infection (cont.)\n" + "![](images/image_a_and_c.png){ width=100% style=\"display: block; margin-left: auto; margin-right: auto; border-radius: 8px;\" }\n" + "\n" + "\n" + "<!-- ![](images/image18.png){ width=70% }\n" + "\n" + "![](images/image19.png){ width=70% }\n" + "\n" + "![](images/image20.png){ width=70% }\n" + "\n" + "![](images/image21.png){ width=70% } -->\n" + "\n" + "## Laboratory diagnosis\n" + "\n" + "- Initial evaluation\n" + "  - Clinical assessment + LFTs ALT AST ALP total bilirubin\n" + "  - CBC and coagulation INR if severe\n" + "\n" + "- Staging and specimens\n" + "  - FibroScan or liver biopsy for fibrosis\n" + "  - Serum or plasma for testing\n" + "\n" + "- Molecular testing\n" + "  - HBV DNA quantitative PCR — viral load and treatment guide\n" + "  - Genotype testing when indicated\n" + "\n" + "## Laboratory diagnosis (cont.)\n" + "- Serology\n" + "  - HBsAg — current infection\n" + "  - HBeAg — high replication and infectivity\n" + "  - Anti-HBs — immunity from recovery or vaccine\n" + "  - Anti-HBc IgM — recent infection\n" + "  - Anti-HBc total — prior or current infection not from vaccine\n" + "\n" + "![](images/image22.png){ width=100% style=\"display: block; margin-left: auto; margin-right: auto; border-radius: 8px;\" }\n" + "\n" + ":::{.notes}\n" + "- HBeAg: secreted during active replication; indicates high infectivity\n" + "- Anti-HBc IgM: marker of recent infection; persists ~6 months\n" + ":::\n" + "\n" + "\n" + "## Treatment prevention and control {.font14}\n" + "\n" + "- Acute HBV\n" + "  - Supportive care and monitoring\n" + "  - Antivirals for fulminant or severe disease per specialist\n" + "\n" + "- Chronic HBV\n" + "  - Goals suppress viral replication prevent progression to cirrhosis and HCC\n" + "  - First-line antivirals tenofovir disoproxil fumarate TDF tenofovir alafenamide TAF entecavir\n" + "  - Pegylated interferon for selected patients\n" + "  - Avoid agents with high resistance when possible\n" + "\n" + "## Treatment prevention and control (cont.) {.font14}\n" + "\n" + "- Prevention and public health\n" + "  - Universal infant vaccination with timely birth dose within 24 hours\n" + "  - HBIG plus vaccine for infants of HBsAg positive mothers\n" + "  - Screening of blood organ donors and pregnant women\n" + "  - Safe injection practices needle exchange harm reduction and safe sex counseling\n" + "\n" + "- Patient counselling\n" + "  - Explain transmission routes alcohol avoidance and adherence to monitoring and therapy\n" + "  - Refer to hepatology or infectious diseases for treatment and long term follow up\n" + "\n" + "\n" + "# HEPATITIS C VIRUSES\n" + "\n" + "## Overview\n" + "\n" + "- Major cause of non‑A/non‑B hepatitis, formerly common post‑transfusion\n" + "- ~170 million global carriers, ~4 million in US\n" + "- Bloodborne transmission with high chronicity\n" + "- Chronic infection → cirrhosis and hepatocellular carcinoma\n" + "- Incubation 6–12 weeks\n" + "\n" + "## Structure\n" + ":::{.columns}\n" + ":::{.column width=\"60%\"}\n" + "- Genus Hepacivirus\n" + "- Family Flaviviridae\n" + "- Size 30–60 nm\n" + "- Envelope, icosahedral\n" + "- Genome +ssRNA ~9.1 kb single ORF\n" + "- Encodes ~10 proteins\n" + "- Envelope glycoproteins E1 E2\n" + ":::\n" + ":::{.column width=\"40%\"}\n" + "![](images/image24.png){ width=70% }\n" + ":::\n" + ":::\n" + "\n" + "## Replication {.font14}\n" + "\n" + ":::{.columns}\n" + ":::{.column width=\"65%\"}\n" + "- Host: humans and chimpanzees; tropism: hepatocytes\n" + "- Entry: receptor-mediated endocytosis and endosomal fusion\n" + "- Genome: +ssRNA functions as mRNA → translated → polyprotein \n" + "- Replication: (+)RNA → dsRNA replicative intermediate → new (+) genomes\n" + "- Assembly/release: buds into ER as lipoviroparticles, secreted via VLDL pathway\n" + "- Immune evasion: inhibits IFN signaling and apoptosis (PKR, TNF pathways)\n" + ":::\n" + ":::{.column width=\"35%\"}\n" + "![](images/image27.jpg){ width=100% }\n" + ":::\n" + ":::\n" + "<!-- ![](images/image25.jpeg){ width=70% }\n" + "![](images/image26.png){ width=70% } -->\n" + "\n" + "## Pathogenesis and immunity {.font14}\n" + "\n" + "- Invades B and T lymphocytes and monocytes then infects hepatocytes\n" + "- Promotes cell survival leading to persistent infection\n" + "- Cell-mediated immunity mediates viral clearance and liver injury\n" + "- Chronic infection exhausts CD8 T cells and impairs viral elimination\n" + "- Histology shows inflammation, portal and periportal fibrosis, and lobular necrosis\n" + "- Chronic inflammation and regeneration increase hepatocellular carcinoma risk\n" + "- Anti-HCV antibodies are not protective\n" + "\n" + "## Epidemiology\n" + "\n" + "- Transmission: bloodborne, sexual\n" + "- High risk: people who inject drugs, transfusion/organ recipients, tattoo recipients, hemophiliacs\n" + "- Global burden: ~58 million chronically infected, ~350k deaths/year\n" + "\n" + "## Clinical syndromes\n" + "\n" + "- Acute: often asymptomatic; ~15% clear infection\n" + "- Chronic: ~70–80% progress to chronic infection with risk of cirrhosis and HCC\n" + "- Common symptom: persistent fatigue\n" + "\n" + "## Diagnosis\n" + "\n" + "- Anti‑HCV antibody screening, confirm with HCV RNA by RT-PCR\n" + "- Use viral load for treatment monitoring\n" + "\n" + "## Treatment and prevention\n" + "\n" + "- Direct‑acting antivirals (E.g Glecaprevir) achieve cure in >90% of cases\n" + "- Prevent: blood screening, harm reduction (needle programs), safe tattooing, avoid alcohol\n" + "\n" + "# HEPATITIS G VIRUS\n" + "\n" + "## Overview & transmission\n" + "- GBV‑C (human pegivirus, HPgV) — enveloped, +ssRNA, ≈9.3 kb\n" + "- Bloodborne, sexual, and perinatal spread\n" + "- Often chronic and asymptomatic\n" + "\n" + "## Clinical significance\n" + "- No consistent link to clinical hepatitis\n" + "- Clearance associated with anti‑E2 antibodies\n" + "\n" + "## Diagnosis\n" + "- GBV‑C RNA by RT‑PCR for active infection\n" + "- Anti‑E2 indicates prior cleared infection\n" + "\n" + "## Treatment & prevention\n" + "- No specific therapy or vaccine\n" + "- Prevent via blood safety and infection control\n" + "\n" + ":::{.notes}\n" + "This virus first discovered in patients with unexplained hepatitis in the 1990s.\n" + "It is not linked to hepatitis.\n" + "Name GBV-C: George Bush Hospital \n" + ":::\n" + "\n" + "# HEPATITIS D VIRUS\n" + "\n" + "## Overview\n" + "\n" + "- HDV infects ~15 million people worldwide and increases fulminant hepatitis risk\n" + "- Defective satellite virus requiring HBsAg for assembly and spread\n" + "- Relies on HBV for envelope and hepatocyte entry\n" + "- Encodes one protein and depends on host enzymes for replication\n" + "\n" + "## Structure and replication {.font14}\n" + ":::{.columns}\n" + ":::{.column width=\"65%\"}\n" + "- Genome: circular negative ssRNA ~1700 nt forming rodlike structure by base pairing\n" + "- Virion: ~35–37 nm, delta Ag core wrapped by HBsAg envelope\n" + "- Delta antigen: small 24 kDa and large 27 kDa forms with distinct roles\n" + "- Replication: host RNA polymerase II transcribes genome, ribozyme cleavage, RNA editing generates large delta Ag for packaging\n" + ":::\n" + ":::{.column width=\"35%\"}\n" + "![](images/image29.png){ width=100% style=\"display: block; margin-left: auto; margin-right: auto; border-radius: 8px;\" }\n" + ":::\n" + ":::\n" + "\n" + "## Pathogenesis\n" + "\n" + "- Occurs only with HBV coinfection or superinfection\n" + "- Superinfection of chronic HBV often causes more severe and rapidly progressive liver disease\n" + "- Liver injury from direct cytopathic effects of HDV plus immune mediated damage\n" + "\n" + "![](images/image30.png){ width=70% style=\"display: block; margin-left: auto; margin-right: auto; border-radius: 8px;\" }\n" + "\n" + "## Diagnosis\n" + "\n" + "- HDV RNA by RT‑PCR or anti‑HDV antibodies by ELISA\n" + "- Test patients with acute or severe HBV disease and chronic HBV carriers with worsening liver injury\n" + "\n" + "## Treatment and prevention\n" + "\n" + "- No widely approved specific antiviral for HDV in many regions\n" + "- Manage underlying HBV and refer to hepatology for emerging therapies and trials\n" + "- Prevent HDV by HBV vaccination and blood safety measures\n" + "\n" + "\n" + "\n" + "# HEPATITIS E VIRUS\n" + "\n" + "## Hepatitis E virus\n" + "\n" + "- HEV: fecal–oral, waterborne outbreaks from contaminated water\n" + "- Taxonomy: Hepeviridae, genus Hepevirus\n" + "- Structure: nonenveloped icosahedral +ssRNA, ~27–34 nm\n" + "- Epidemiology: outbreaks in low‑resource regions; sporadic zoonotic cases elsewhere\n" + "- Genotypes: 1–2 mainly human (waterborne); 3–4 zoonotic (pigs)\n" + "\n" + "## Hepatitis E virus (cont.)\n" + "- Clinical: acute, HAV‑like illness; usually not chronic in immunocompetent hosts\n" + "- Severity: mortality ~1–2%; markedly higher (~20%) in third‑trimester pregnancy\n" + "- Prevention: safe water, sanitation, hygiene; vaccine licensed in some countries\n" + "- Diagnosis: anti‑HEV IgM and HEV RNA by RT-PCR for acute infection\n" + "\n" + "\n" + "# Quiz\n" + "\n" + "## Which of the following Hepatitis viruses is typically transmitted through the fecal-oral route?{.quiz-question}\n" + "\n" + "- Hepatitis B  \n" + "- Hepatitis C  \n" + "- [Hepatitis A]{.correct}  \n" + "- Hepatitis D  \n" + "\n" + "\n" + "## Which Hepatitis virus is most likely to cause chronic infection in adults?{.quiz-question}\n" + "\n" + "- Hepatitis A  \n" + "- [Hepatitis B]{.correct}  \n" + "- Hepatitis E  \n" + "- Hepatitis G  \n" + "\n" + "## What is the primary mode of transmission for Hepatitis C virus?{.quiz-question}\n" + "\n" + "- Fecal-oral  \n" + "- [Bloodborne]{.correct}  \n" + "- Sexual contact only  \n" + "- Airborne  \n" + "\n" + "## Which Hepatitis virus requires coinfection with Hepatitis B virus to replicate?{.quiz-question}\n" + "\n" + "- Hepatitis A  \n" + "- Hepatitis C  \n" + "- [Hepatitis D]{.correct}  \n" + "- Hepatitis E  \n" + "\n" + "\n" + "## What is the most effective prevention method for Hepatitis B virus infection?{.quiz-question}\n" + "\n" + "- Hand washing  \n" + "- [Vaccination]{.correct}  \n" + "- Safe water  \n" + "- Condom use  \n" + "\n" + "## Which Hepatitis virus has the highest mortality rate during pregnancy?{.quiz-question}\n" + "\n" + "- Hepatitis A  \n" + "- Hepatitis B  \n" + "- Hepatitis C  \n" + "- [Hepatitis E]{.correct}\n" + "\n" + "## What type of genome does Hepatitis B virus have?{.quiz-question}\n" + "\n" + "- Single-stranded RNA  \n" + "- Double-stranded RNA  \n" + "- Single-stranded DNA  \n" + "- [Double-stranded DNA]{.correct}\n" + "\n" + "## Which Hepatitis virus is classified in the Flaviviridae family?{.quiz-question}\n" + "\n" + "- Hepatitis A  \n" + "- Hepatitis B  \n" + "- [Hepatitis C]{.correct}  \n" + "- Hepatitis D \n" + "\n" + "## References\n" + "\n" + "- Adapted from training material: Chhay Sokdalis (PharmD).\n" + "- Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. 7th ed. Elsevier; 2013.\n" + "- Ryan KJ, Ray CG, editors. Sherris Medical Microbiology. 6th ed. McGraw-Hill; 2014.\n" + "- Riedel S, Morse S, Mietzner T, Miller S, editors. Jawetz, Melnick & Adelberg’s Medical Microbiology. McGraw-Hill; 2019.\n" + "- Mishra B. Textbook of Medical Virology. 2nd ed. CBS Publishers & Distributors; 2022.\n" + "\n" + ""</script>
<script> window._input_filename = '/Users/sopheap/Desktop/UP/Virology/6_Hepatitis_virus/6_Hepatitis_viruses.qmd'</script>
<div id="refs" class="references csl-bib-body" role="list">
<div id="ref-ChhaySodalis2025" class="csl-entry" role="listitem">
<div class="csl-left-margin">1. </div><div class="csl-right-inline">Sokdalis C. Virology training materials. 2024. </div>
</div>
<div id="ref-ViralZone" class="csl-entry" role="listitem">
<div class="csl-left-margin">2. </div><div class="csl-right-inline">Hulo C, Masson P, de Castro E, Le Mercier P. Vol. 39, Nucleic Acids Research. 2011 [cited 2025 Oct 24]. p. D708–13 ViralZone: A knowledge resource to understand virus diversity. Available from: <a href="https://viralzone.expasy.org/">https://viralzone.expasy.org/</a></div>
</div>
<div id="ref-Louten2016" class="csl-entry" role="listitem">
<div class="csl-left-margin">3. </div><div class="csl-right-inline">Louten J. Essential human virology. London, UK; San Diego, CA, USA; Cambridge, MA, USA; Oxford, UK: Elsevier (Academic Press); 2016. </div>
</div>
<div id="ref-ShuklaSaha" class="csl-entry" role="listitem">
<div class="csl-left-margin">4. </div><div class="csl-right-inline">Das S, Saha R. Microbiology practical manual, third edition. New Delhi, India: CBS Publishers &amp; Distributors Pvt Ltd; n.d. </div>
</div>
<div id="ref-Mishra2022" class="csl-entry" role="listitem">
<div class="csl-left-margin">5. </div><div class="csl-right-inline">Mishra B. Textbook of medical virology, second edition. New Delhi, India: CBS Publishers &amp; Distributors Pvt. Ltd.; 2022. </div>
</div>
<div id="ref-Patricia2017" class="csl-entry" role="listitem">
<div class="csl-left-margin">6. </div><div class="csl-right-inline">Tille PM. Bailey &amp; scott’s diagnostic microbiology, 14th edition. 14th ed. St. Louis, Missouri, USA: Elsevier; 2017. </div>
</div>
<div id="ref-Kudesia2009" class="csl-entry" role="listitem">
<div class="csl-left-margin">7. </div><div class="csl-right-inline">Kudesia G, Wreghitt T. Clinical and diagnostic virology. Cambridge, UK; New York, USA; Melbourne, Australia; Madrid, Spain; Cape Town, South Africa; Singapore; São Paulo, Brazil: Cambridge University Press; 2009. </div>
</div>
<div id="ref-Knipe2022" class="csl-entry" role="listitem">
<div class="csl-left-margin">8. </div><div class="csl-right-inline">Knipe DM, Howley PM. Fields virology: Emerging viruses. 7th ed. Vol. 1. Wolters Kluwer; 2022. </div>
</div>
</div>
</section></section>
    </div>
  <div class="quarto-auto-generated-content" style="display: none;">
<div class="footer footer-default">

</div>
</div></div>

  <script>window.backupDefine = window.define; window.define = undefined;</script>
  <script src="6_Hepatitis_viruses_files/libs/revealjs/dist/reveal.js"></script>
  <!-- reveal.js plugins -->
  <script src="6_Hepatitis_viruses_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.js"></script>
  <script src="6_Hepatitis_viruses_files/libs/revealjs/plugin/pdf-export/pdfexport.js"></script>
  <script src="6_Hepatitis_viruses_files/libs/revealjs/plugin/reveal-menu/menu.js"></script>
  <script src="6_Hepatitis_viruses_files/libs/revealjs/plugin/reveal-menu/quarto-menu.js"></script>
  <script src="6_Hepatitis_viruses_files/libs/revealjs/plugin/reveal-quiz/quiz.js"></script>
  <script src="6_Hepatitis_viruses_files/libs/revealjs/plugin/appearance/appearance.js"></script>
  <script src="6_Hepatitis_viruses_files/libs/revealjs/plugin/reveal-confetti/confetti.js"></script>
  <script src="6_Hepatitis_viruses_files/libs/revealjs/plugin/verticator/verticator.js"></script>
  <script src="6_Hepatitis_viruses_files/libs/revealjs/plugin/revealeditable/editable.js"></script>
  <script src="6_Hepatitis_viruses_files/libs/revealjs/plugin/reveal-pointer/pointer.js"></script>
  <script src="6_Hepatitis_viruses_files/libs/revealjs/plugin/quarto-support/support.js"></script>
  

  <script src="6_Hepatitis_viruses_files/libs/revealjs/plugin/notes/notes.js"></script>
  <script src="6_Hepatitis_viruses_files/libs/revealjs/plugin/search/search.js"></script>
  <script src="6_Hepatitis_viruses_files/libs/revealjs/plugin/zoom/zoom.js"></script>
  <script src="6_Hepatitis_viruses_files/libs/revealjs/plugin/math/math.js"></script>
  <script>window.define = window.backupDefine; window.backupDefine = undefined;</script>

  <script>

      // Full list of configuration options available at:
      // https://revealjs.com/config/
      Reveal.initialize({
'controlsAuto': true,
'previewLinksAuto': true,
'pdfSeparateFragments': false,
'autoAnimateEasing': "ease",
'autoAnimateDuration': 1,
'autoAnimateUnmatched': true,
'jumpToSlide': true,
'pdfMaxPagesPerSlide': 1,
'menu': {"side":"left","useTextContentForMissingTitles":true,"markers":false,"loadIcons":false,"custom":[{"title":"Tools","icon":"<i class=\"fas fa-gear\"></i>","content":"<ul class=\"slide-menu-items\">\n<li class=\"slide-tool-item active\" data-item=\"0\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.fullscreen(event)\"><kbd>f</kbd> Fullscreen</a></li>\n<li class=\"slide-tool-item\" data-item=\"1\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.speakerMode(event)\"><kbd>s</kbd> Speaker View</a></li>\n<li class=\"slide-tool-item\" data-item=\"2\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.overview(event)\"><kbd>o</kbd> Slide Overview</a></li>\n<li class=\"slide-tool-item\" data-item=\"3\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.togglePdfExport(event)\"><kbd>e</kbd> PDF Export Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"4\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.toggleScrollView(event)\"><kbd>r</kbd> Scroll View Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"5\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.keyboardHelp(event)\"><kbd>?</kbd> Keyboard Help</a></li>\n</ul>"}],"openButton":true},
'quiz': {"checkKey":"c","resetKey":"q","shuffleKey":"t","allowNumberKeys":true,"disableOnCheck":false,"shuffleOptions":true,"defaultCorrect":"","defaultIncorrect":"","includeScore":false,"disableReset":false},
'appearance': {"hideagain":true,"delay":300,"debug":false,"appearevent":"slidetransitionend","autoappear":false,"autoelements":false,"appearparents":false,"theme":"simple","darktheme":"black"},
'confetti': {"particleCount":150,"angle":90,"spread":360,"startVelocity":25,"decay":0.9,"gravity":0.65,"drift":0,"ticks":400,"colors":["#0366fc","#f54281","#1fd14f"],"shapes":null,"scalar":0.7,"zIndex":100,"disableForReducedMotion":false},
'verticator': {"themetag":"h1","color":"","inversecolor":"","skipuncounted":false,"clickable":true,"position":"auto","offset":"3vmin","autogenerate":true,"tooltip":false,"scale":1,"debug":true},
'pointer': {"key":"q","color":"#ff0000","pointerSize":12,"alwaysVisible":false,"tailLength":15},
'smaller': false,
 
        // Display controls in the bottom right corner
        controls: false,

        // Help the user learn the controls by providing hints, for example by
        // bouncing the down arrow when they first encounter a vertical slide
        controlsTutorial: false,

        // Determines where controls appear, "edges" or "bottom-right"
        controlsLayout: 'edges',

        // Visibility rule for backwards navigation arrows; "faded", "hidden"
        // or "visible"
        controlsBackArrows: 'faded',

        // Display a presentation progress bar
        progress: true,

        // Display the page number of the current slide
        slideNumber: 'c/t',

        // 'all', 'print', or 'speaker'
        showSlideNumber: 'all',

        // Add the current slide number to the URL hash so that reloading the
        // page/copying the URL will return you to the same slide
        hash: true,

        // Start with 1 for the hash rather than 0
        hashOneBasedIndex: false,

        // Flags if we should monitor the hash and change slides accordingly
        respondToHashChanges: true,

        // Push each slide change to the browser history
        history: true,

        // Enable keyboard shortcuts for navigation
        keyboard: true,

        // Enable the slide overview mode
        overview: true,

        // Disables the default reveal.js slide layout (scaling and centering)
        // so that you can use custom CSS layout
        disableLayout: false,

        // Vertical centering of slides
        center: false,

        // Enables touch navigation on devices with touch input
        touch: true,

        // Loop the presentation
        loop: false,

        // Change the presentation direction to be RTL
        rtl: false,

        // see https://revealjs.com/vertical-slides/#navigation-mode
        navigationMode: 'linear',

        // Randomizes the order of slides each time the presentation loads
        shuffle: false,

        // Turns fragments on and off globally
        fragments: true,

        // Flags whether to include the current fragment in the URL,
        // so that reloading brings you to the same fragment position
        fragmentInURL: false,

        // Flags if the presentation is running in an embedded mode,
        // i.e. contained within a limited portion of the screen
        embedded: false,

        // Flags if we should show a help overlay when the questionmark
        // key is pressed
        help: true,

        // Flags if it should be possible to pause the presentation (blackout)
        pause: true,

        // Flags if speaker notes should be visible to all viewers
        showNotes: false,

        // Global override for autoplaying embedded media (null/true/false)
        autoPlayMedia: null,

        // Global override for preloading lazy-loaded iframes (null/true/false)
        preloadIframes: null,

        // Number of milliseconds between automatically proceeding to the
        // next slide, disabled when set to 0, this value can be overwritten
        // by using a data-autoslide attribute on your slides
        autoSlide: 0,

        // Stop auto-sliding after user input
        autoSlideStoppable: true,

        // Use this method for navigation when auto-sliding
        autoSlideMethod: null,

        // Specify the average time in seconds that you think you will spend
        // presenting each slide. This is used to show a pacing timer in the
        // speaker view
        defaultTiming: null,

        // Enable slide navigation via mouse wheel
        mouseWheel: false,

        // The display mode that will be used to show slides
        display: 'block',

        // Hide cursor if inactive
        hideInactiveCursor: true,

        // Time before the cursor is hidden (in ms)
        hideCursorTime: 5000,

        // Opens links in an iframe preview overlay
        previewLinks: false,

        // Transition style (none/fade/slide/convex/concave/zoom)
        transition: 'fade',

        // Transition speed (default/fast/slow)
        transitionSpeed: 'default',

        // Transition style for full page slide backgrounds
        // (none/fade/slide/convex/concave/zoom)
        backgroundTransition: 'none',

        // Number of slides away from the current that are visible
        viewDistance: 3,

        // Number of slides away from the current that are visible on mobile
        // devices. It is advisable to set this to a lower number than
        // viewDistance in order to save resources.
        mobileViewDistance: 2,

        // The "normal" size of the presentation, aspect ratio will be preserved
        // when the presentation is scaled to fit different resolutions. Can be
        // specified using percentage units.
        width: 1280,

        height: 720,

        // Factor of the display size that should remain empty around the content
        margin: 0.1,

        // Bounds for smallest/largest possible scale to apply to content
        minScale: 0.2,

        maxScale: 1.5,

        math: {
          mathjax: 'https://cdn.jsdelivr.net/npm/mathjax@2.7.9/MathJax.js',
          config: 'TeX-AMS_HTML-full',
          tex2jax: {
            inlineMath: [['\\(','\\)']],
            displayMath: [['\\[','\\]']],
            balanceBraces: true,
            processEscapes: false,
            processRefs: true,
            processEnvironments: true,
            preview: 'TeX',
            skipTags: ['script','noscript','style','textarea','pre','code'],
            ignoreClass: 'tex2jax_ignore',
            processClass: 'tex2jax_process'
          },
        },

        // reveal.js plugins
        plugins: [QuartoLineHighlight, PdfExport, RevealMenu, RevealQuiz, Appearance, RevealConfetti, Verticator, Revealeditable, RevealPointer, QuartoSupport,

          RevealMath,
          RevealNotes,
          RevealSearch,
          RevealZoom
        ]
      });
    </script>
    document.addEventListener('DOMContentLoaded', function() {
      // Create toggle button immediately
      const toggleBtn = document.createElement('button');
      toggleBtn.id = 'night-mode-toggle';
      toggleBtn.innerHTML = '🌙';
      toggleBtn.title = 'Toggle Night Mode';
      toggleBtn.style.cssText = `
        position: fixed;
        top: 10px;
        right: 10px;
        width: 30px;
        height: 30px;
        border-radius: 50%;
        background: #007bff;
        color: white;
        border: 1px solid white;
        font-size: 15px;
        cursor: pointer;
        z-index: 10000;
        transition: all 0.3s ease;
        display: flex;
        align-items: center;
        justify-content: center;
        box-shadow: 0 3px 6px rgba(0,0,0,0.3);
      `;

      // Add hover effect
      toggleBtn.onmouseover = function() {
        this.style.background = '#0056b3';
        this.style.transform = 'scale(1.1)';
      };
      toggleBtn.onmouseout = function() {
        this.style.background = '#007bff';
        this.style.transform = 'scale(1)';
      };

      // Add click handler
      toggleBtn.onclick = function() {
        document.body.classList.toggle('night-mode');
        
        // Update button icon based on current mode
        setTimeout(function() {
          if (document.body.classList.contains('night-mode')) {
            toggleBtn.innerHTML = '☀️';
            toggleBtn.title = 'Switch to Light Mode';
          } else {
            toggleBtn.innerHTML = '🌙';
            toggleBtn.title = 'Switch to Night Mode';
          }
        }, 100);
      };

      // Add to page
      document.body.appendChild(toggleBtn);
      console.log('Button added to body');
      
    });

    <script id="quarto-html-after-body" type="application/javascript">
      window.document.addEventListener("DOMContentLoaded", function (event) {
        const tabsets =  window.document.querySelectorAll(".panel-tabset-tabby")
        tabsets.forEach(function(tabset) {
          const tabby = new Tabby('#' + tabset.id);
        });
        const isCodeAnnotation = (el) => {
          for (const clz of el.classList) {
            if (clz.startsWith('code-annotation-')) {                     
              return true;
            }
          }
          return false;
        }
        const onCopySuccess = function(e) {
          // button target
          const button = e.trigger;
          // don't keep focus
          button.blur();
          // flash "checked"
          button.classList.add('code-copy-button-checked');
          var currentTitle = button.getAttribute("title");
          button.setAttribute("title", "Copied!");
          let tooltip;
          if (window.bootstrap) {
            button.setAttribute("data-bs-toggle", "tooltip");
            button.setAttribute("data-bs-placement", "left");
            button.setAttribute("data-bs-title", "Copied!");
            tooltip = new bootstrap.Tooltip(button, 
              { trigger: "manual", 
                customClass: "code-copy-button-tooltip",
                offset: [0, -8]});
            tooltip.show();    
          }
          setTimeout(function() {
            if (tooltip) {
              tooltip.hide();
              button.removeAttribute("data-bs-title");
              button.removeAttribute("data-bs-toggle");
              button.removeAttribute("data-bs-placement");
            }
            button.setAttribute("title", currentTitle);
            button.classList.remove('code-copy-button-checked');
          }, 1000);
          // clear code selection
          e.clearSelection();
        }
        const getTextToCopy = function(trigger) {
          const outerScaffold = trigger.parentElement.cloneNode(true);
          const codeEl = outerScaffold.querySelector('code');
          for (const childEl of codeEl.children) {
            if (isCodeAnnotation(childEl)) {
              childEl.remove();
            }
          }
          return codeEl.innerText;
        }
        const clipboard = new window.ClipboardJS('.code-copy-button:not([data-in-quarto-modal])', {
          text: getTextToCopy
        });
        clipboard.on('success', onCopySuccess);
        if (window.document.getElementById('quarto-embedded-source-code-modal')) {
          const clipboardModal = new window.ClipboardJS('.code-copy-button[data-in-quarto-modal]', {
            text: getTextToCopy,
            container: window.document.getElementById('quarto-embedded-source-code-modal')
          });
          clipboardModal.on('success', onCopySuccess);
        }
          var localhostRegex = new RegExp(/^(?:http|https):\/\/localhost\:?[0-9]*\//);
          var mailtoRegex = new RegExp(/^mailto:/);
            var filterRegex = new RegExp('/' + window.location.host + '/');
          var isInternal = (href) => {
              return filterRegex.test(href) || localhostRegex.test(href) || mailtoRegex.test(href);
          }
          // Inspect non-navigation links and adorn them if external
         var links = window.document.querySelectorAll('a[href]:not(.nav-link):not(.navbar-brand):not(.toc-action):not(.sidebar-link):not(.sidebar-item-toggle):not(.pagination-link):not(.no-external):not([aria-hidden]):not(.dropdown-item):not(.quarto-navigation-tool):not(.about-link)');
          for (var i=0; i<links.length; i++) {
            const link = links[i];
            if (!isInternal(link.href)) {
              // undo the damage that might have been done by quarto-nav.js in the case of
              // links that we want to consider external
              if (link.dataset.originalHref !== undefined) {
                link.href = link.dataset.originalHref;
              }
            }
          }
        function tippyHover(el, contentFn, onTriggerFn, onUntriggerFn) {
          const config = {
            allowHTML: true,
            maxWidth: 500,
            delay: 100,
            arrow: false,
            appendTo: function(el) {
                return el.closest('section.slide') || el.parentElement;
            },
            interactive: true,
            interactiveBorder: 10,
            theme: 'light-border',
            placement: 'bottom-start',
          };
          if (contentFn) {
            config.content = contentFn;
          }
          if (onTriggerFn) {
            config.onTrigger = onTriggerFn;
          }
          if (onUntriggerFn) {
            config.onUntrigger = onUntriggerFn;
          }
            config['offset'] = [0,0];
            config['maxWidth'] = 700;
          window.tippy(el, config); 
        }
        const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
        for (var i=0; i<noterefs.length; i++) {
          const ref = noterefs[i];
          tippyHover(ref, function() {
            // use id or data attribute instead here
            let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
            try { href = new URL(href).hash; } catch {}
            const id = href.replace(/^#\/?/, "");
            const note = window.document.getElementById(id);
            if (note) {
              return note.innerHTML;
            } else {
              return "";
            }
          });
        }
        const findCites = (el) => {
          const parentEl = el.parentElement;
          if (parentEl) {
            const cites = parentEl.dataset.cites;
            if (cites) {
              return {
                el,
                cites: cites.split(' ')
              };
            } else {
              return findCites(el.parentElement)
            }
          } else {
            return undefined;
          }
        };
        var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
        for (var i=0; i<bibliorefs.length; i++) {
          const ref = bibliorefs[i];
          const citeInfo = findCites(ref);
          if (citeInfo) {
            tippyHover(citeInfo.el, function() {
              var popup = window.document.createElement('div');
              citeInfo.cites.forEach(function(cite) {
                var citeDiv = window.document.createElement('div');
                citeDiv.classList.add('hanging-indent');
                citeDiv.classList.add('csl-entry');
                var biblioDiv = window.document.getElementById('ref-' + cite);
                if (biblioDiv) {
                  citeDiv.innerHTML = biblioDiv.innerHTML;
                }
                popup.appendChild(citeDiv);
              });
              return popup.innerHTML;
            });
          }
        }
      });
      </script>
    

</body></html>